恒瑞医药：子公司HRS-7535片临床试验获批

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-7535 tablets, which will be conducted soon. The drug is intended for the treatment of chronic kidney disease [1] Group 1 - The approval for the clinical trial indicates progress in the development of HRS-7535 tablets [1] - The targeted indication for HRS-7535 is chronic kidney disease, highlighting the company's focus on addressing significant health issues [1]